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of Alzheimer’s Disease Pathologies 
Dakota C. Johnson  
Department of Pharmacology and Toxicology, Brody School of Medicine, 
Greenville N.C. 27858 
 
ABSTRACT – It is been estimated that nearly 5 million Americans suffer from Alzheimer’s 
Disease (AD), making finding its cause one of medicine’s top priorities. It has long been 
known that genetics plays a major role in the development of Alzheimer’s Disease, but this 
does not fully explain why or when the disease manifests itself. Alzheimer’s is likely not a 
single-origin disease, but rather a disease that arises from a combination of both genetic and 
environmental factors that occur in the “right mix” at the “right time” to produce a phenotype 
indicative of AD. A major component of Alzheimer’s is the plaques of amyloid-β that form 
in the brains of its victims. One of the cells in the brain that has been shown to control the 
levels of amyloid-β is the microglia, though scientists debate over exactly how microglia 
does this. Studies show that these microglia experience a “critical window” of heightened 
susceptibility to environmental contaminants early in development from post-natal day 
(PND) 5-15. In this study, 3x-Tg-AD mice were dosed during this critical window with a 
proven neurotoxicant, lead acetate, in the form of drinking water. The levels and states of 
microglia were observed and compared to the levels of control mice. Taking this a step 
further, the levels of amyloid-β were tested using enzyme-linked immunosorbent assay 
(ELISA). This study hopes to uncover the relationship between microglia and amyloid-β 
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levels as well as determine whether introduction of an environmental toxicant (i.e. lead) 
during a period of heightened susceptibility could exacerbate the onset of AD pathologies 
later in life. In the end, no major correlation could be detected. The ELISA showed 
inconclusive evidence to provide a correlation between the environmental contaminants and 
amyloid-β levels. Complementary evidence, however, suggests that there may have been a 
flaw in the ELISA methodology. We believe this because confocal images show accumulated 
amyloid-β in the brain, but each ELISA result yielded that the levels were below the limits of 
detection. The DeWitt lab plans to revamp its methods and replicate this project because it 
represents a novel undertaking in science and the results have the potential to make waves to 
drastically change how Alzheimer’s Disease is analyzed and how it can be prevented. 
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    Introduction 
Alzheimer’s Disease and Amyloid-β 
Alzheimer’s Disease (AD) is a late-onset neural 
disease that affects basic brain functions like memory and 
thinking skills. Those afflicted with Alzheimer’s Disease 
have neurofibrillary tangles and plaques made up of 
amyloid-β protein throughout the brain (USDHHS, 
2012). This can be seen in Figure 1. AD pathogenesis is 
widely believed to be driven by the production and 
deposition of these amyloid-beta peptides, which hinder 
neuron to neuron signaling at the synapse and eventually 
leads to cell death (Murphy & Levine, 2010).  
Microglial Effects on Amyloid-β 
One cell that is associated with amyloid-β plaques in the AD brain is the microglia, 
the innate immune cells of the brain. Microglia act as microphages in the central nervous 
system, clearing cellular debris and dead neurons through the process of phagocytosis. It is 
very controversial whether microglia have a beneficial or detrimental function (Dheen et al. 
2007). Some studies show that microglia actually reduce AD pathology by phagocytosing 
amyloid-β, while others suggest that, when activated, microglia increases the deposition of 
amyloid proteins (amyloidosis) (Weitz & Town, 2012). A visual of activated vs. ramified 
microglia can be seen in Figure 2. In a recent review of microglia in health and disease, Saijo 
and Glass (2011) emphasized that existing data is insufficient to rule microglia as exclusively 
Figure 1: Visual depiction of 
AD progression 
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neuroprotective or neurodegenerative in the AD brain. Microglia may protect the brain by 
phagocytosing amyloid-β and clearing plaques in AD pathology but alternatively, amyloid-β 
may activate microglia, induce pro-
inflammatory mediators and lead to 
subsequent neuron elimination. This brings 
up another plausible explanation that 
microglia may additionally increase 
neurodegeneration through the secretion of 
proinflammatory signals. One study suggests 
that in response to accumulating amyloid-β 
proteins, microglia generate a toxic 
inflammatory response that accelerates synaptic 
and neuronal injury. It is a persistent and 
nonresolving inflammatory response and is a key feature in the development of Alzheimer's 
disease (Woodling et al. 2014). Many proinflammatory signaling pathways are linked to the 
development of neurodegeneration. This process also plays a major role in other 
neurodegenerative diseases like Parkinson's disease, prion diseases, and multiple sclerosis 
(Dheen et al. 2007).  Further studies support this claim by saying that the presence of acute 
phase proteins and oxidative damage proves that amyloid-β plaques are the foci of local 
inflammatory responses. This same study shows that fibrillar forms of amyloid-β have been 
shown to activate tyrosine kinase-dependent signal transduction cascades, resulting in 
inflammatory responses in microglia (McDonald et al. 1998). Despite the controversy, it is 
widely agreed upon that the actions of microglia in AD, whether detrimental or beneficial, 
Figure 2: Activated vs.  
Ramified Microglia 
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depend on the conditions under which the microglia encounter AD pathologies (Weitz & 
Town, 2012). 
Critical Windows 
Despite being a late-onset disease, usually occurring after the age of 60, the origins of 
Alzheimer’s may arise very early in development, long before the brain has reached full 
maturity (Basha et al. 2005). Microglia experience a “critical window” during development, 
or a period of heightened susceptibility to disturbances such as aberrant protein expression 
associated with congenital genetic mutations or exposures to exogenous agents such as 
environmental contaminants. These disturbances can potentially reprogram the organism and 
increase the risk of disease later in life. Moreover, mounting evidence suggests that 
developmental exposure to environmental agents leads to latent neurotoxicity in adult 
organisms (Bash et al, 2005). Alzheimer’s is likely not a single-origin disease, but rather a 
disease that arises from a combination of both genetic and environmental factors that occur in 
the “right mix” at the “right time” to produce a phenotype indicative of AD.  
Goal and Overview 
 In this project, we hypothesize that early-life exposure to a neurotoxic chemical (i.e. 
lead) would alter the microglia, making them over or under sensitive to aberrant protein 
expression in the brain, and lead to the early onset of Alzheimer’s Disease pathologies. 
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Therefore, the goal of this project is to evaluate a critical window of microglial susceptibility 
to an environmental agent in a vulnerable 
genetic model, the 3x-Tg-AD mouse, and 
correlate changes in microglial number and 
activity with early-onset AD pathologies, such 
as amyloid-β levels.  Detrimental interactions 
of a developing organism with environmental 
factors during susceptible windows of 
development are putative pathways to myriad 
diseases later in life. For example, early life 
exposure to tobacco smoke increases the risk of 
childhood asthma, which subsequently increases the risk of additional diseases in adulthood, 
including obesity, behavioral disorders, lung cancer, and  allergies (D ietert e    
Insults during  developm ent, w hether from  altered p   associated with a 
genetic  m utation or from  signaling d        
potentially  reprogram  an orga            
diseases later  in life. This can be seen in Figure 3. Diseases of aging such as  A D  are 
thought to arise from developmental  reprogramming, and evidence  suggests that 
microglia, the resident  m acrophages            
pathology. 
Importance 
This project is important because it further adds to our knowledge and understanding 
of the cellular mechanisms of AD and related neurodegenerative diseases as they relate to 
Figure 3: A general schematic of how 
environmental and genetic risk factors may 
contribute to clinical diseases in the aged, 
including additional lifetime risks. This proposal 
will consider both environmental and genetic risk 
factors as well as normal aging in an innovative 
model that evaluates both cellular and molecular 
markers of Alzheimer’s disease pathology. 
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microglia. It also represents a very novel 
undertaking, as it has been the first project 
to explore the impacts of both   
environmental agents and critical 
windows of developmental susceptibility in AD.  
 As we are specifically focused on the 
etiologic synergism between 
environmental agent exposure and genetic 
vulnerability as a double-hit model that more closely mimics realistic exposures than does a 
single-hit model, we hope to provide a robust model of AD. This double-hit model is 
outlined in Figure 4. Additionally, as AD is likely a disease of developmental 
reprogramming, this study will be particularly useful in designing early-intervention 
treatment strategies that focus on developmental processes. While many published studies 
report on the effects of aging microglia in the Alzheimer’s brain, few studies have evaluated 
developmental impacts to microglia and subsequent AD pathologies. 
Figure 4: Schematic depicting potential 
mechanistic pathways to be explored. Solid lines 
indicate known pathways whereas dashed lines 
indicate potential pathways. 
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Methods 
Background 
 In a 2005 study, Basha et al. exposed Long-Evans rats to lead (as lead acetate) in 
drinking water during early development from postnatal day (PND) one through PND20 and 
examined several endpoints relevant to AD, including levels of amyloid precursor protein 
(APP) and amyloid-β in brains of aged rats. They also exposed a different group of rats to 
lead during senescence (18-20 months of age) to determine if later life exposure to an 
environmental agent increased markers of AD. In developmentally exposed rats, markers of 
AD were transiently expressed in young animals (i.e., PND50) and were overexpressed in 
these animals as they aged. In rats exposed during senescence, no changes in markers were 
noted. Therefore, Basha concluded that developmental exposure to lead produced latent 
effects on genes associated with neurodegenerative processes during old age and that 
developmental events influenced later life neurodegenerative changes. Due to these findings, 
we assessed our animals at ages relevant to the 3x-Tg-AD mouse: PND50, three months of 
age (PND90), and six months of age (PND 180). 
Experimental Approach 
Our experimental approach included an exposure period encompassing a critical 
window of susceptibility for microglia. During prenatal development, microglial colonization 
of the brain occurs and their numbers increase dramatically between PND5 and PND15 
(Harry and Kraft, 2012). This postnatal period represents a critical window of susceptibility 
for microglia, where their numbers increase and their phenotypes mature (Harry and Kraft, 
2012). It is this window that we are interested in disrupting with lead exposure. 
The study began with 24 triple-transgenic dams that were predisposed to develop 
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Alzheimer’s disease. Therefore, our model can be seen as a push model. Of these 24 dams, 
12 were labeled as control and the remaining 12 labeled as treated. Once each dam had her 
litter, they were culled to no more than six animals per dam, balanced by sex, if possible. A 
low dose of lead as lead acetate (100 parts per million) was administered to the mice via 
gavage dosing. The concentration of 100 parts per million has been shown to be well within 
the range of human consumption and gavage dosing is a reliable and safe way to dose the 
animal. Animals were given 0.1 mL of dosing solution per 10 g of daily body weight. 
Offspring were examined daily from PND5-PND21  and any deviations from general health, 
growth, and behavior were noted. At PND21, all offspring were weaned and placed in a same 
sex sibling group. At PND50, PND 90, and PND 180, one offspring of each sex per litter (if 
possible) will be evaluated for microglia and AD endpoints.  
The AD endpoint that I was responsible for during my time in the DeWitt lab was 
analysis of the amyloid-β levels. After euthanasia, brains of both the control and treated 
offspring were taken out and subsequently had the hippocampus removed. Amyloid-β levels 
were then determined by an enzyme-linked immunosorbent assay (ELISA). A BetaMark 
Beta Amyloid x-42 ELISA kit, manufactured by Covance, was used. 
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Results 
 A two-sample t-test was performed on each age group to determine if the data was 
significantly different and if the changes in the data could have happened by chance. In the 
end, no significant difference was detected between the absorbance values of the control and 
treated populations in any age group. A standard curve was created by plotting the mean 
absorbance for each standard concentration (x axis) against amyloid-β concentration (Y axis) 
in pg/mL. We then drew a best fit curve through the points in the graph and found that each 
value obtained in both the control and treated groups were below the limits of detection for 
the ELISA.  
 In the PND 50 age group, control groups showed a mean ELISA absorbance value of 
0.1425 while the treated group showed a mean of 0.1516. The p-value associated with this 
age group was 0.37. Table 1 shows this data. 
 In the PND 90 age group, control groups showed a mean ELISA absorbance value of 
0.1739 while the treated group showed a mean of 0.1310. The p-value associated with this 
age group was 0.108. Table 2 shows this data. 
 In the PND 180 age group, control groups showed a mean ELISA absorbance value 
of 0.0512 while the treated group showed a mean of .0498. The p-value associated with this 
age group was 0.505. Table 3 shows this data. 
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 Rather than reject the null hypothesis that early-life exposure to a neurotoxic 
chemical (i.e. lead) would alter microglia and lead to the early onset of Alzheimer’s Disease 
pathologies (i.e. increased amyloid-β deposition), the DeWitt lab feels that further 
investigation should be completed to see if these values are actually indicative of the true 
values or if a flaw in methodology could be the problem. 
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 t-Test: Two-Sample Assuming Equal Variances 
  Age: 50; Control versus Treated 
    Control Treated 
Mean 0.1425 0.1516 
Variance 0.000112833 0.0002683 
Observations 4 5 
Pooled Variance 0.000201671 
 Hypothesized Mean Difference 0 
 df 7 
 t Stat -0.955240986 
 P(T<=t) one-tail 0.185636145 
 t Critical one-tail 1.894578604 
 P(T<=t) two-tail 0.371272289 
 t Critical two-tail 2.364624251   
  
Table 1: PND 50 Statistics
18 
 
 t-Test: Two-Sample Assuming Equal Variances 
  
Age: 90; Control versus Treated 
  
  Control Treated 
Mean 0.173857143 0.1308 
Variance 0.00265681 0.0025909 
Observations 7 10 
Pooled Variance 0.002617264 
 Hypothesized Mean Difference 0 
 df 15 
 t Stat 1.707835423 
 P(T<=t) one-tail 0.054136656 
 t Critical one-tail 1.753050325 
 P(T<=t) two-tail 0.108273312 
 
t Critical two-tail 2.131449536   
  
Table 2: PND 90 Statistics
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 t-Test: Two-Sample Assuming Equal Variances 
  
Age: 180; Control versus Treated 
  
  Control Treated 
Mean 0.051222222 0.0498 
Variance 1.66319E-05 0.000008075 
Observations 9 5 
Pooled Variance 1.37796E-05 
 Hypothesized Mean Difference 0 
 df 12 
 t Stat 0.686895904 
 P(T<=t) one-tail 0.252603188 
 t Critical one-tail 1.782287548 
 P(T<=t) two-tail 0.505206375 
 
t Critical two-tail 2.178812827   
  
Table 3: PND 180 Statistics
20 
 
   
Figure 5: Graph of Mean ELISA Absorbance Values (control vs. treated) 
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Discussion 
 
Innovation 
  
This research project was truly a novel one. We know that in some individuals, AD 
arises from genetic mutations. We also suspect that environmental influences contribute to 
the risk of AD in individuals regardless of genetic makeup and that microglia play a role in 
AD pathologies. We do not know, however, how genetic vulnerability and environmental 
insults interact to result in AD pathologies. Our project takes an innovative turn away from 
traditional, single risk factor approaches to develop a robust model of AD that incorporates 
the dual risk factors of genetic vulnerability and an environmental insult. Thus, our model of 
detrimental exogenous interactions with a genetic vulnerability more closely approximates 
developmental scenarios experienced in a real world scenario. Additionally, by evaluating 
things like microglia, APP gene expression, or in this case, levels of amyloid-β, we can start 
to tease apart the cellular and molecular mechanisms that lead to AD pathologies under a 
system of gene x environment interactions. The risk of AD attributable to genetics is about 
70% (Vilatela et al., 2012). However, “genetics” does not denote just heritable mutations, it 
includes mutations induced by, for example, exposure to exogenous agents that disrupt 
protein expression and ultimately, a functional endpoint. Our project is particularly 
innovative because it combines a heritable mutation with exposure to a well-known 
neurotoxic agent, lead. By examining AD endpoints like levels of amyloid-β, we can 
determine if developmental exposure to lead impacts traditional indicators of AD known to 
be exacerbated in the 3x-Tg-AD mouse model. Layering on microglia number and 
morphology with co-localization of amyloid-β will provide additional novel data about the 
early-life role of a cell known to be associated with AD pathologies and will provide insight 
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into whether microglia play a neuroprotective or neurodegenerative role in AD. 
Analysis of Results 
Being that this project was so innovative, it came with a large number of unknowns. 
It is a natural occurrence that novel research must sometimes undergo a series of “growing 
pains” before truly significant and meaningful data collection can occur. Everything from the 
homogenization procedure to which ELISA kit to use was a result of literature reviews and 
making educated guesses, but in the end, the DeWitt lab feels we may need to repeat this 
study and make a few adjustments to our methodology. We remain confident that our 
hypothesis is a valid one. The major reason we feel this way is because the lab took a 
confocal image of a PND 90 male (Figure 6) brain that showed significant amounts of 
amyloid-B expression, as well as colocalization with microglia. This tells us that amyloid-β 
IS present in the brains of the animals, yet every animal came back well below the ELISA’s 
limit of detection. Therefore, we can assume that a major problem we face deals with the 
homogenization procedure. One problem could stem from the amyloid-β becoming denatured 
for some reason during homogenization. We will need to take a look at the chemicals and 
mixtures and how they may possibly have had an adverse affect of the protein structures or 
concentrations. Another explanation could simply be we did not use enough brain tissue to 
get an accurate reading. Though we are not as concerned with absolute concentration as we 
are relative concentrations, we thought that approximately ½ of the hippocampus should have 
yielded enough amyloid-β to be detected, but that may not be the case. In the future, we plan 
to experiment with this to find out exactly how much of the brain needs to be used. It is 
possible that the entire hippocampus or even the entire brain may need to be homogenized 
and used in the ELISA in order to yield proper results. 
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 Figure 6:  Picture from a male control PND90 with amyloid-beta in red (Cy5 fluorophore), 
microglia in green (FITC fluorophore) and the overlap in yellow.  
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